Messages people are sending
These are real letters, emails, and call scripts that supporters wrote and then chose to share with us. Every one is published with its author's permission and only after a person reviewed it. Nothing written with the tools on this site reaches us unless its author ticks a box and presses send.
Email Alex Scheffler, Omaha, NE
Subject: Please preserve research access to SR-17018 — a constituent in recovery
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from Omaha, Nebraska. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from Omaha, Nebraska. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. Please Delay or narrow the emergency scheduling of SR-17018 specifically. Separate SR-17018 from other listed compounds and review it on its own merits. Publish the compound-specific evidence being relied upon. Preserve lawful research and medical-development access to SR-17018. Involve HHS/FDA scientific and medical review before any placement. Avoid blocking potential opioid-withdrawal research before it can be studied. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do. Sincerely, Alex Scheffler 2339 BENSON GARDENS BLVD Omaha, Nebraska 68134 alexschefflerincarnate@gmail.com 14026868015 Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email + printed letter Michael Tuft, Bronx, NY
Subject: Please preserve research access to SR-17018 — a constituent in recovery
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from Bronx, New York. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. I am on suboxone maintenance. I have been on for 3 years. I try to get off though it's very hard. I stated using vicoden at 18 due to a acl and minuscus tore in my knee. I later started taking oxycodone at age 20, i became addicted and by age 22 i was using heroin intravenously. I went to prison from age 25 to 30 and then from 31 to 37. Even after getting out i continued to struggle and stopped using illicit drugs in September 2023. I would love to have something i could take that would have me not feel withdrawals and be able to stop taking in 2 weeks and be drug and withdrawal free. So many people i grew up with died from overdose from fentanyl and heroin including my daughters mother family members and numerous best friends. If this could help people and stop this crisis that had been going on more for over 20 years it would be great. I am now 41 years old and wish there was something like this a long time ago. I don't blame no one but myself for my choices and mistakes. Though substances played a large part and one that could do good should ne given a chance. Especially if it has helped many people already. Thank you. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email + printed letter Anonymous — GA
Subject: Preserve research access to SR-17018 — support compound-specific review
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from [city withheld], Georgia with an interest in medical research and public health. Emergency Schedule I placement can significantly chill legitimate research by adding registration, supply, and administrative barriers. Given credible anecdotal signals around opioid-withdrawal, this compound warrants compound-specific scientific review before prohibition. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email + printed letter Anonymous — MS
Subject: Please preserve research access to SR-17018 — a constituent in recovery
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from [city withheld], Mississippi. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. I have to take prescription opiates everyday to be able to work . To be able to do anything. I'm always in severe pain . I am disabled but I am back working now because disability doesn't pay enough . So I can't survive without opiates for now . But if there is some kind of better way for people to get off opioids without suicides . I believe we should have access as a basic human right ! Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email Brian Keith Lauterbach, Plano, TX
Subject: Please preserve research access to SR-17018 — a constituent in recovery
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from Plano, Texas. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. Scaremongering does not work, placing this substance in Schedule 1 prior to giving it a chance to be studied and used to help those of us in chronic pain where applicable. This proposed ban looks to do much more harm than good and I am quite sure that the lawmakers have no idea what is about to happen when this takes effect and the outcome has more risks than benefit to the general public. Please overlook the greedy lobby and consider your constituents that need your help right now. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email + printed letter Anonymous — NY
Subject: Please preserve research access to SR-17018 — a constituent in recovery
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from [city withheld], New York. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. I am addicted to fetynal and I have such a hard time stopping even taking methadone I can’t seem to kick it because the withdrawal is so bad please don’t ban this SR-17018 I understand opiates keep big pharma in business but the world needs this after how many people fetynal killed Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email + printed letter Cameron Ledbetter, Knoxville, TN
Subject: Please preserve research access to SR-17018 — a constituent in recovery
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from Knoxville, Tennessee. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. My name is Cam and I’m reaching out to say I’ve struggled with addiction my whole life, but I am not a bad person. I’ve always worked hard, kept a job, and never stolen or begged. Like many, I turned to substances simply to escape deep emotional pain caused by those I love most. Addicts are sick, not evil—and it could happen to anyone. The agony of withdrawal and the trap of opioid dependency is a suffering that is impossible to understand unless you've lived through it, I wouldn’t wish it on anyone. Prohibition has never worked. Instead of repeating the same failed approaches, we need new solutions. Please allow SR-17 to be fully researched. If it offers a way to bring relief to desperate, broken people without the high or severe side effects of current options, it deserves a chance to save lives. Thank you for your time and I hope you have a great day. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email + printed letter shane elliott idleman, phoenix, AZ
Subject: Please preserve research access to SR-17018 — a constituent in recovery
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from phoenix, Arizona. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. I cant get off of illicit fentanyl and i so desperately want off, after 20 years of destroying my life and relationships Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email + printed letter Julian Caggiano, Brooklyn, NY
Subject: Please preserve research access to SR-17018 — a constituent in recovery
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from Brooklyn, New York. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. I have been addicted to oxycodone since I was 15 years old. I’m now 30. Dealing with chronic pain and receiving help is next to impossible. I probably wouldn’t even write this if non cancerous pain was treated the way it should be. Now people are forced to play Russian roulette with fentanyl or fentanyl analogs. It’s disgusting and we’re tired of the fake bs about getting it out of the US. That will never happen due to the government clearly wanting people on this poison and god forbid get oxycodone. SR has made it so I am no longer in a bear trap and can live my life as I should. To stop SR would be the same as not stopping fentanyl use and the availability of fentanyl. Stop letting big pharmaceutical companies run this country we’re tired of the games. No one wants suboxone or methadone it’s all poison. Either stop telling drs to stop addressing pain or allow SR to be legal. No one will continue to put up with being poisoned I know I won’t. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email + printed letter Anonymous — NV
Subject: Please preserve research access to SR-17018 — a constituent in recovery
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from [city withheld], Nevada. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. I have been using opioids for 10+ yrs and I want nothing more than to get clean. I want to go back to when I have never touched any opioid. I want my life back and I hate methadone. I hate going to the clinic 5 days a week because there isn't one in my town I have to take 3 buses to the next town to get to the clinic every day by noon cuz they close at noon and if I want a full time job then I have to choose between going to the clinic to get clean or working and making money but then spending all my money on trying to stay well enough to get out of bed everyday to go to work. So if there is a miracle drug that will get me clean asap then I want it now. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email + printed letter Anonymous — MD
Subject: Please preserve research access to SR-17018 — a constituent in recovery
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from [city withheld], Maryland. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. I was suck on suboxone for years was having hard time tapering. Since pharma start making them impossible to split in lower doseages. 1mmx1mm sq. Found Sr17 on reddit. Started with a plan and came off suboxone after 7 years of being on suboxone. And came off In 2 weeks with the help of Sr17018. Scheduling this miracle medicine along with 7ohis only cause more deaths in our communities. Thanks for taking your to time hear me out. Please help make change and give this miracle a chance. It doesn't get you high. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Phone call script Anonymous — NC
Hi, my name is [name withheld], and I live in [city withheld], North Carolina. I'm calling about DEA's temporary scheduling notice involving SR-17018, also referred to as 5,6-dichloro desmethylchlorphine. I'm asking my representative, my senators, the DEA and the FDA and HHS to urge DEA and HHS to delay or narrow emergency scheduling of SR-17018 specifically, separate it from other compounds, publish compound-specific evidence, and preserve lawful research access. This is personal for me — my own recovery is affected by whether compounds like this can be studied through lawful medical channels. People are reporting that SR-17018 may have important opioid-withdrawal applications, and it should be studied before being placed into Schedule I. Thank you for your time.
Email + printed letter Evan T Sommers, Phoenix, AZ
Subject: Please preserve research access to SR-17018
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from Phoenix, Arizona to add my voice. I believe that when there are credible reports of an opioid-withdrawal benefit, the responsible course is urgent, compound-specific research — not emergency prohibition that could block that research. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email + printed letter Anonymous — VA
Subject: Please preserve research access to SR-17018 — a concerned family member
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from [city withheld], Virginia. I am contacting you as someone who has watched a person I care about struggle with opioid addiction. Families like mine need more researched options for reducing withdrawal, not fewer research pathways. My mother had used heroin for about 5 years of her life before passing away in November. I watched as her body and mind deteriorated until she was no longer able to function. She has used when she was younger, but quit for a good 10+ years, but came back around to it. Those last 5 years, and the years before that made my life quite difficult as neglect and abuse were common. I am now living my own life, and love my mother as I understand her battle was not an easy one, but I wish that SR-17018 was available to help her quit. Maybe, if she had quit soon enough, I would still have my mother today and I wouldn't have to go about learning how to live life completely on my own. Maybe if SR-17018 had existed, and its medical use was properly documented and offered, thousands of kids and people out there would not have to live the life I've lived. I feel very proud of myself for taking care of my mother and myself, and my ability to persist even with my home life, but I still wish everyday that things were different. I wish everyday that my mother was still here. I wish that heroin wasn't a problem and we didn't have to worry about it. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email + printed letter Anonymous — TN
Subject: Please preserve research access to SR-17018 — a constituent in recovery
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from [city withheld], Tennessee. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. SR-17018 played a major role in helping me overcome opioid dependence. After struggling with severe withdrawal, it allowed me to stop using opioids with very little discomfort while remaining functional enough to continue working and managing my daily responsibilities. Although medications like methadone and buprenorphine help many people, I wanted to avoid transitioning to another long-acting opioid medication. In my experience, SR-17018 provided another path. I believe compounds like SR-17018 deserve further scientific research rather than being banned outright. Removing access before their potential is fully understood is not in society's best interest and could eliminate a promising harm reduction tool for people trying to overcome opioid dependence. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email Anonymous — CA
Subject: Concerns about overbroad emergency scheduling of SR-17018
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from [city withheld], California. I am concerned that bundling SR-17018 into a broad emergency scheduling action, without compound-specific evidence and without HHS/FDA scientific review, is an overbroad use of emergency authority that can foreclose promising research before the public-health value is understood. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email + printed letter Philip Hull, Sherborn, MA
Subject: Please preserve research access to SR-17018 — a constituent in recovery
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from Sherborn, Massachusetts. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. SR17018 is in the same class of Opioid Orphines as Buprenorphine. In fact it has way less tolerance than Buprenorphine. This compound has great potential in the treatment of opioid dependency & should be studied further in treating patients with opioid addiction. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Shared with permission and reviewed before publication. Authors who shared anonymously are shown only by state — their name and city were removed in their own browser and never sent to us. If you shared a message and want it taken down, ask us to delete it; our privacy policy explains what we keep.